Cynviloq: Pivotal trial started

Sorrento began the crossover, open-label, international, pivotal bioequivalence TRIBECA trial to compare 260 mg/m 2 IV Cynviloq vs. 260 mg/m 2 IV Abraxane nab-paclitaxel in about 100 patients with me...